Dasiglucagon Demonstrates Reduced Costs in the Treatment of Severe Hypoglycemia in a Budget Impact Model

admin.veranex : Mar 24, 2025 10:22:50 PM

Commercial Strategy & Market Access

Jordan Hinahara and Thomas Goss, members of our Commercial Strategy and Market Access team, contributed to the budget impact model. The objective was to evaluate the economic impact of dasiglucagon compared with available glucagon treatments for SHE management, considering direct cost of treatment and health care resource utilization.

Read the Model

Meeting Early Phase Study Challenges – a Data Management Perspective

Gary Keeler : Mar 24, 2025 10:23:06 PM

First-in-Human studies are a discovery point, which can decide the fate of a compound as well as lay the groundwork for subsequent phases of a...

Read More

Webinar: Precision Medicine and Alzheimer’s Disease: Overcoming Biomarker Testing Barriers for Alzheimer’s Disease Patients

Susannah Ashcroft : Mar 24, 2025 10:22:45 PM

Tuesday, October 03, 2023 | 12pm EDT / 11am CDT / 9am PDT / 5pm BST (UK) / 6pm CEST (EU-Central)

Read More
Addressing Heart Failure with IFPx

1 min read

Addressing Heart Failure with IFPx

Gary Keeler : Mar 24, 2025 10:22:43 PM

Recently two Veranex employees volunteered their time and expertise to IFPx — a company working on a device to monitor and proactively treat...

Read More